SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as investors discuss the potential impact of its earnings report on the broader tech sector, especially regarding AI and advertising revenue. Community members are weighing in on whether the company can maintain margins while scaling AI, while also considering the possibility of a stock split. Anticipation is high as META prepares to release earnings amidst a bullish phase for the technology sector.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending as investors react to earnings beats and significant Azure cloud growth, though some express concern over valuation and guidance, leading to a stock dip. The community is actively debating whether the dip is a buying opportunity or a sign of broader market concerns, especially regarding AI spending and growth sustainability. Cloud growth and the company's OpenAI stake remain key talking points for potential upside.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet's stock is trending after reporting better-than-expected Q3 earnings, driven by strong growth in ad revenue, YouTube, and cloud services. Community members are bullish, citing the company's leadership in AI and potential for further growth, with some setting price targets as high as $1000. The discussion highlights Alphabet's role as a key player in the tech sector and its continued dominance in search and AI.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending as investors discuss its upcoming earnings report and the potential impact of AI and cloud growth. Community members are weighing the possibility of an earnings beat and a rise to new price levels, while also considering whether growth is already priced in. News of a Google partnership is also circulating.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana ($CVNA) is trending amid discussions about its upcoming earnings report and concerns around subprime auto loan delinquencies. Community members are debating the potential for a post-earnings pump, with some citing the company's history of surprising the market, while others express skepticism about its fundamentals and accounting practices. The stock's high volatility and significant short interest are also fueling active conversations.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as investors anticipate upcoming earnings and debate whether recent gains are sustainable, with many eyeing the $200 mark. Community discussions revolve around the stock's high valuation and potential for a stock split. Bullish sentiment is fueled by the company's perceived leadership in AI and partnerships, while bears caution against an overextended valuation.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies is trending as investors discuss the potential impact of interest rate decisions and upcoming earnings. Community members are weighing the possibility of a short squeeze against concerns about insider selling and the company's alignment with broader market trends. Discussions also revolve around the company's acquisitions and their potential to drive future growth.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is trending due to a significant stock plunge following a disappointing earnings report and slashed full-year guidance, sparking discussions about whether it's a buying opportunity or the start of a downtrend. The community is analyzing the potential for a recovery, noting its low P/E ratio, while also weighing concerns about debt and leadership changes. Some traders are eyeing short-term bounces, while long-term investors assess the company's fundamentals amidst the volatility.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle's stock is trending amidst mixed sentiment following its recent earnings announcement; while some investors express concern over the company's forecast and CEO performance, others see it as a buying opportunity, citing the brand's long-term potential. Community discussions revolve around earnings results, with some debating whether recent performance justifies the stock's valuation in the competitive fast-casual sector.

Stride, Inc. is a technology-based educational company, which engages in the provision of proprietary and third-party curriculum, software systems and educational services. It also offers online curriculum and career services to middle and high school students, under the Destinations Career Academy brand name. The company was founded by Ronald J. Packard in 2000 and is headquartered in Reston, VA.

Stride Inc

Stride Inc ($LRN) is trending amid a significant stock drop, sparking intense debate on its valuation and future prospects. The catalyst appears to be weak forward guidance attributed to technology platform rollout issues, leading to customer dissatisfaction. The community is dissecting the earnings beat versus the guidance miss, with some viewing the sell-off as an overreaction and others questioning the company's fundamentals and long-term growth potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

X4 Pharmaceuticals (XFOR) Upgraded to Strong Buy: What Does It Mean for the Stock?

X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

X4 Pharmaceuticals (XFOR) announced on Wednesday that it will reduce its workforce by 50% as part of a strategic restructuring.The workforce reduction is expected to result in annualized cost savings of approximately $13 million, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-announces-restructuring-business-operations">said.</a> The strategic restructuring is aimed at aligning resources to complete the late-stage trial of Mavorixafor in patients with moderate and severe chronic neutropenia, it added.Shares of the company traded 0.5% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/XFOR">XFOR stock</a> rose from 'bearish' to 'neutral' territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.The Boston-headquartered firm announced that Chief Legal and Compliance Officer Natasha Thoren, Chief Operating Officer Mary DiBiase, and Chief Commercial Officer Mark Baldry will be exiting the company as part of the workforce reduction. Chief Medical Officer Christophe Arbet‑Engels, meanwhile, is resigning for personal reasons, it added.“Over the coming weeks, we plan to continue to drive operational efficiencies, consolidate resources, and strengthen our leadership structure. With these changes, we expect to be well-positioned to become a world‑class hematology company, beginning with the advancement of mavorixafor into chronic neutropenia,” said Executive Chairman Adam Craig.The company also appointed its President, John Volpone, as the COO, and he will now oversee day‑to‑day operational management and business execution in his expanded role. Craig, meanwhile, will oversee clinical development.The company’s Mavorixafor is marketed as Xolremdi in the U.S. for the treatment of people aged 12 years and older with WHIM syndrome — a rare, primary immunodeficiency disorder that impairs white blood cell movement from the bone marrow to the bloodstream. The company is now evaluating additional uses of Mavorixafor and is conducting a global, pivotal late-stage clinical trial in people with certain chronic neutropenic disorders. Neutropenia is characterized by an abnormally low number of neutrophils, a type of white blood cell essential for fighting bacterial and fungal infections.XFOR stock is down by about 85% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-says-asthma-drug-failed-trial-in-smokers-disease/chDGnwkRd64">AstraZeneca Says Asthma Drug Failed Trial In Smoker’s Disease</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

X4 Pharma To Halve Headcount Amid Efforts To Complete Neutropenia Trial

The workforce reduction is expected to result in annualized cost savings of approximately $13 million, the company said.

Equity

The workforce reduction is expected to result in annualized cost savings of approximately $13 million, the company said.


X4 Pharmaceuticals (XFOR) on Wednesday announced the closing of an upsized private placement of over 11 million shares of common stock and pre-funded warrants to purchase nearly 49 million shares of common stock for total offering proceeds of $85 million.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-announces-closing-upsized-85-million-private">said</a> that the originally announced offering of $60 million was increased to allow for the inclusion of an investor who had a pre-existing investment right.<a href="https://stocktwits.com/symbol/XFOR">X4</a> intends to use the net proceeds from the offering for continued development towards a potential additional approval of Mavorixafor in chronic neutropenia, in addition to the commercialization of the drug for the treatment of WHIM syndrome.On Stocktwits, retail sentiment around the stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:631/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_13_at_9_57_21_AM_png_cea6672fbd.webp" alt="XFOR's Sentiment Meter and Message Volume as of 9:55 a.m. ET on Aug. 13, 2025 | Source: Stocktwits" width="631" height="61"><figcaption>XFOR's Sentiment Meter and Message Volume as of 9:55 a.m. ET on Aug. 13, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about the placement and the additional funding.<stembedurl>https://stocktwits.com/Sir_Falstaff/message/624932917</stembedurl>However, another user opined that the stock would trade 200% higher if the news were that positive.<stembedurl>https://stocktwits.com/FreedoniaT/message/624925751</stembedurl>H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm's price target for the XFOR stock to $3.50 from $7 and kept a ‘Buy’ rating on the shares, according to The Fly.The firm updated the company's model to reflect the second-quarter (Q2) report and the private placement. The capital raised strengthens the balance sheet and aids in meeting the Hercules Loan covenant obligations, the analyst told investors in a research note.X4 on Tuesday announced that its President and Chief Executive Officer, Paula Ragan, and Chief Financial Officer Adam Mostafa have stepped down from their respective roles.X4 Board of Directors appointed Adam Craig as Executive Chair, John Volpone as President, and David Kirske as Chief Financial Officer, effective immediately.XFOR stock is down 86% this year and 83% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ppi-report-wall-street-awaits-wholesale-inflation-data-for-cues-fed-rate-cut/chrCQjNRd9J">PPI Report: Wall Street Awaits Wholesale Inflation Data For Further Cues On Fed’s Rate Path Ahead</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

X4 Pharmaceuticals Stock Rises On Closing Of Upsized Offering, But Brokerage Lowers Price Target

The company said that the originally announced offering of $60 million was increased to $85 million to allow for the inclusion of an investor who had a pre-existing investment right.

X4 Pharmaceuticals Unveils Corporate Presentation for Investors

X4 Pharmaceuticals (XFOR) has shared an update. X4 Pharmaceuticals, Inc. has recently made their latest corporate presentation available to the pub...

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that...

Commit To Buy X4 Pharmaceuticals At $1, Earn 48.2% Annualized Using Options

Investors considering a purchase of X4 Pharmaceuticals Inc (XFOR) shares, but tentative about paying the going market price of 1.40/share, might benefit from considering selling puts among the...

X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences

BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that...

X4 Pharmaceuticals on the Brink: The Race Against Nasdaq Delisting and Investor Confidence

X4 Pharmaceuticals (XFOR) has disclosed a new risk, in the Share Price & Shareholder Rights category. X4 Pharmaceuticals currently faces the risk o...

Q4 2023 X4 Pharmaceuticals Inc Earnings Call Transcript

Recap: X4 Pharmaceuticals Q4 Earnings

X4 Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. The firm is focused on mavorixafor which is being marketed in the U.S. under the trade name xolremdi. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

X4 Pharmaceuticals Inc

Will Apple (AAPL) beat quarterly earnings? 
 
*Powered by Polymarket

XFOR
X4 Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest XFOR News

XFORX4 Pharmaceuticals Inc